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Background-—In aortic stenosis (AS), symptoms and left ventricular (LV) dysfunction represent a later disease state, and objective
parameters that identify incipient LV dysfunction are needed. We sought to determine prognostic utility of brain natriuretic peptide
(BNP) and left ventricular global longitudinal strain (LV-GLS) in patients with aortic valve area <1.3 cm2.
Methods and Results-—Five-hundred and thirty-one patients between January 2007 and December 2008 with aortic valve area
<1.3 cm2 (86% with aortic valve area ≤1.1 cm2) and left ventricular ejection fraction ≥50% who had BNP drawn ≤90 days from
initial echo were included. Society of Thoracic Surgeons (STS) score and mortality were recorded. Mean STS score, glomerular
ﬁltration rate, and median BNP were 115, 7335 mL/min per 1.73 m , and 141 (60–313) pg/mL, respectively; 78% were in New
York Heart Association class ≥II. Mean LV-stroke volume index (LV-SVI) and LV-GLS were 3910 mL/m2 and 13.93%. At
4.72 years, 405 patients (76%) underwent aortic valve replacement; 161 died (30%). On multivariable survival analysis, age
(hazard ratio [HR] 1.46), New York Heart Association class (HR 1.27), coronary artery disease (HR 1.72), decreasing glomerular
ﬁltration rate (HR 1.15), increasing BNP (HR 1.16), worsening LV-GLS (HR 1.13) and aortic valve replacement (time dependent) (HR
0.34) predicted survival (all P<0.01). For mortality, the c-statistic incrementally increased as follows (all P<0.01): STS score (0.60
[0.58–0.64]), STS score+BNP (0.67 [0.62–0.70]), and STS score+BNP+LV-GLS (0.74 [0.68–0.78]).
Conclusions-—In normal LVEF patients with signiﬁcant aortic stenosis, BNP and LV-GLS provide incremental (additive not
duplicative) prognostic information over established predictors, suggesting that both play a synergistic role in deﬁning outcomes.
( J Am Heart Assoc. 2016;5:e002561 doi: 10.1161/JAHA.115.002561)
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W ith an aging population, the prevalence of aorticstenosis (AS) is on the rise. AS presents as a
continuum and patients are typically asymptomatic for a
period of time, with onset of symptoms marking a key point in
the natural history signiﬁcantly impacting survival.1 Current
guidelines recommend aortic valve replacement (AVR) for
severe AS once symptoms occur or when there is ventricular
systolic dysfunction.2 The presence of signiﬁcant AS in the
absence of symptoms and normal left ventricular ejection
fraction (LVEF) presents a clinical dilemma. Increasingly,
therefore, cardiologists are recognizing that various subtypes
of AS with preserved LVEF have varying outcomes, when
separated based on LV stroke volume index (LV-SVI).3–6 The
clinician must balance the risk of AVR with risk of waiting for
symptoms to develop. Waiting too long may have detrimental
effects, as prior studies have linked severity of preoperative
symptom status with worse postoperative outcome.7 It is
increasingly being recognized that structural LV changes, in
the setting of signiﬁcant AS, may not always be reversible
even after successful valve intervention and may impact long-
term survival, even in those with a normal LVEF. Additionally,
many patients are relatively poor at identifying their symp-
tomatic status due to functional limitation from aging or
medical comorbidities. Thus, there is increasing interest in
using sensitive markers of LV function, other than parameters
derived from contractile function (LVEF or LV-SVI), to
determine outcomes in this population.8–14
Previous studies have established the usefulness of brain
natriuretic peptide (BNP) in patients with AS.12,14–18 These
studies have found that BNP levels correlate with symptom-
free survival, New York Heart Association class, and
survival.12,16,19–21 Left ventricular global longitudinal strain
(LV-GLS), measured using speckle tracking echocardiography,
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is a quantitative measure of early LV dysfunction, enabling
assessment of longitudinally oriented subendocardial myocar-
dial ﬁbers, which are sensitive to ischemia and wall stress in
AS patients. We sought to determine the incremental
prognostic utility of BNP levels and LV-GLS in a contemporary
population of patients with signiﬁcant AS and preserved LVEF.
Methods
Study Design
This was a retrospective observational cohort study of 531
patients who had an echocardiogram at our tertiary center
between January 2007 and January 2008 documenting an
aortic valve area (AVA) ≤1.3 cm2, LVEF ≥50%, without severe
tricuspid/mitral valvular disease and serum BNP measured
obtained close to the incident echocardiogram (>90% on the
same day, all within 90 days) and without signiﬁcant interval
change in clinical status. We excluded patients with a limited
life expectancy due to noncardiac causes (ie, terminal
malignancy, stroke, and advanced lung disease) or death
from noncardiac causes within 90 days of incident echocar-
diogram without having undergone AV surgery (n=15), LVEF
<50% (n=94), and those with poor image quality for strain
assessment (n=31).
Clinical Data
Clinical data were assembled from electronic medical records
after appropriate Institutional Review Board approval. For BNP
assay, all blood samples were collected into EDTA Vacutainer
tubes. Specimens were immediately frozen and plasma was
separated at 4°C. Plasma BNP (pg/mL) was determined by
chemiluminescence immunoassay on site (Biosite Diagnos-
tics, San Diego, CA). Cardiac procedures were as follows: (1)
isolated AVR, (2) AVR and coronary artery bypass grafting, (3)
AVR and ascending aorta repair or replacement +/ coronary
artery bypass grafting, and (4) transcatheter AVR. The
remainder were treated medically. Based on available preop-
erative data, Society of Thoracic Surgeons (STS) score was
calculated. The decision for surgery was made by the
individual treating cardiologists and cardiac surgeons at the
time of clinical evaluation.
Outcomes Assessment
All-cause mortality was considered to be the primary
outcome. Death notiﬁcation was conﬁrmed by inspection of
the death certiﬁcate or veriﬁed with a family member. In
addition, we further categorized death as cardiac, noncardiac
(eg, malignancy, cirrhosis of liver, primary pulmonary/neuro-
logic etiology), or unknown. We also performed survival
analysis for a secondary outcome of deaths, categorized as
cardiac or unknown, but excluding documented noncardiac
deaths (censoring these patients at the time of death). The
duration of follow-up ranged from initial echocardiogram to
death or June 2013.
Echocardiographic Data
All patients underwent a comprehensive echocardiogram with
commercially available instruments (Philips Medical Systems,
General Electric, and Siemens Medical Solutions). Measure-
ments were obtained according to recommendations and
indexed to body surface area.22–24
For quantiﬁcation of AS, LV outﬂow tract (LVOT) diameter
was measured on parasternal long-axis views. Pulsed-wave
and continuous-wave Doppler was used to record velocities
across LVOT and aortic valve (AV), respectively. LV-SVI was
measured using the following formula: LVOTVTI9LVOTarea/
body surface area. A cutoff ≥35 mL/m2 was considered as
preserved LV-SVI.4,23,25,26 AVA was calculated using the
continuity equation and severe AS was deﬁned as AVA
≤1 cm2 or mean AV gradient ≥40 mm Hg. Finally, valvuloar-
terial impedance (mm HgmL1m2), a measure of global LV
afterload, was calculated as follows27: mean AV gradient+sys-
tolic blood pressure/LV-SVI).
In all patients, LV-GLS measurements were obtained from
gray-scale images recorded in apical 2, 3, and 4-chamber
views, using ofﬂine Velocity Vector Imaging (Syngo VVI;
Siemens Medical Solutions, Mountain View, CA). The details
of our protocol have been described previously.28 Measure-
ments were made by an investigator blinded to all clinical
information. LV-GLS was not available to physicians at the
time of surgical decision-making.
Statistical Analysis
Continuous variables are expressed as mean (SD) and/or
median and compared using analysis of variance (normal
distribution) or Mann–Whitney test (non-normal distribution).
Categorical data are expressed as a percentage and com-
pared using v2. Association between continuous variables
was tested using Spearman’s correlation coefﬁcient. To
assess outcomes, multivariable Cox proportional hazards
analysis was utilized. Relevant clinical and echocardiographic
variables, known to be associated with outcomes in AS
patients, were considered. AVR was included as a time-
dependent covariate in Cox analysis. For each patient
undergoing AVR, the analysis time was modeled so that only
the person-time after AVR was included in the surgical group.
The person-time before AVR was included in the nonsurgical
category. Hazard ratios with 95% CI were calculated. To
ensure that proportional hazards assumption was not
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violated, graphical inspection of Schoenﬁeld residuals plot-
ted against time was performed. Additionally, survival curves
for cumulative events as a function over time were obtained
using Cox Proportional Hazards model and adjusted for
relevant variables described above. We assessed the
classiﬁcation of risk using net integrated discrimination
index. In addition, discriminative ability of various survival
models was compared using the c-statistic.29 Statistical
analysis was performed using SPSS version 11.5 (SPSS Inc,
Chicago, IL), Stata version 10.0 (StataCorp, College Station,
TX), and R 3.0.3 (R Foundation for Statistical Computing,
Vienna, Austria). A P-value of <0.05 was considered
signiﬁcant.
Results
The baseline data are shown in Tables 1 and 2. In the study,
the vast majority (n=459, 86%) of the patients had AVA
≤1 cm2, while 72 (16%) had moderate AS (AVA [1–1.3 cm2]).
There were no major clinical differences between these
subgroups, except for higher age (7212 versus
6516 years), higher proportion of symptoms (87% versus
65%), higher STS score (11.55% versus 8.54%), and higher
median BNP (145 versus 92 pg/mL) in those with severe
versus moderate AS (all P<0.05). Similarly, indexed LV mass
(11945 versus 9332 g/m2), mean aortic valve gradient
(4516 versus 2210 mm Hg), and AVA (0.70.2 versus
1.20.1 cm2) were signiﬁcantly worse in severe AS versus
moderate AS (all P<0.01). Median LV-GLS was 13.9%
(interquartile range 16.3% to 11.5%), and slightly worse in
severe versus moderate AS (13.6% versus 14.2%, P=0.04).
LV-GLS had a statistically signiﬁcant but weak association
with LVEF (b 0.3, P<0.001) and LV-SVI (b 0.20, P<0.001),
indexed LV mass (b 0.19, P<0.001), and BNP (b 0.24,
P<0.001). Similarly, there was a signiﬁcant but weak asso-
ciation between BNP and LVEF (b 0.14, P=0.002) and
indexed LV mass (b 0.20, P<0.001), but no association with
LV-SVI (b 0.04, P=0.3).
Mean LV-GLS values (%) for each BNP quartile were as
follows: quartile 1 (15.23), quartile 2 (14.33), quartile
3 (13.43), and quartile 4 (12.64), P<0.001. The mean
LV-SVI values (mL/m2) for each LV-GLS quartile were as
follows: quartile 1 (4110), quartile 2 (3910), quartile 3
(3910), and quartile 4 (359), P<0.001. The median BNP
values (pg/mL) for LV-GLS quartiles were as follows: quartile
1 (95 [41–212]), quartile 2 (109 [44–204]), quartile 3 (154
[60–307]), and quartile 4 (228 [97–429]), P<0.001. Finally,
the mean LV-SVI values for each BNP quartile were as follows:
quartile 1 (4011), quartile 2 (3810), quartile 3 (3810),
and quartile 4 (389), P=0.4.
Overall, 405 patients (76%) underwent AVR and 126 (24%)
were treated medically. Of the AVR patients, 179 (44%)
Table 1. Baseline Characteristics of the Study Population
Variable
Total Population
(n=531)
Age, y 71 (12)
Male sex 58%
BSA, m2 0.3
Angina 34%
Syncope 6%
NYHA Class
I 22%
II 44%
III 28%
IV 7%
Any symptoms 84%
Hypertension 79%
Hyperlipidemia 78%
Diabetes mellitus 23%
Prior stroke 8%
Smoking history 51%
Obstructive CAD 59%
Atrial fibrillation 22%
Prior OHS 23%
ICD 4%
Pacemaker 38%
Society of thoracic surgeons score 11.(5)
b-Blockers 86%
ACE inhibitors 45%
Aspirin 90%
Statins 74%
Diuretics 89%
Aldosterone receptor blocker 9%
Hemoglobin, mg/dL 13 (2)
GFR, mL/min per 1.73 m2 73 (35)
LDL, mg/dL 96 (40)
HDL, mg/dL 50 (17)
Median BNP with IQL, pg/mL 141 [60–313]
BNP quartiles
1st (0-59) 25%
2nd (60–141) 25%
3rd (142–313) 25%
4th (>313) 25%
All continuous variables reported as mean (SD). ACE indicates angiotensin-converting
enzyme; BNP, brain natriuretic peptide; BSA, body surface area; CAD, coronary artery
disease; GFR, glomerular ﬁltration rate; HDL, high-density lipoprotein; ICD, internal
cardioverter deﬁbrillator; IQL, interquartile range; LDL, low-density lipoprotein; NYHA,
New York Heart Association; OHS, open heart surgery.
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underwent isolated surgical AVR, 18 (4%) underwent
transcatheter AVR, and the rest underwent a combination
procedure (AVR+ coronary artery bypass grafting +/ aortic
surgery+/ mitral/tricuspid valve repair). There was no
difference in LV-GLS in patients requiring concomitant
coronary artery bypass grafting (13.63% versus
13.94%, respectively, P=0.1). The relevant parameters of
the study sample, divided on whether they underwent AVR
versus medical therapy, are shown in Table 3.
Outcomes and Survival Data
During 4.72 years of follow-up, mortality was observed in
161 (30%) patients (6 [1%] deaths within 30 days post-AVR).
The breakdown of deaths was as follows: 94 (58%) cardiac, 17
(11%) documented noncardiac, and 49 (31%) unknown
(however, none of them had a clearly documented noncardiac
etiology to account for death). The proportion of deaths was
similar between severe and moderate AS (137 [30%] versus
24 [33%]), with no difference in survival during follow-up
(P=0.1).
Results of multivariable Cox Proportional Hazard Survival
analysis (for all-cause mortality) are shown in Table 4A and
4B. The v2 for all-cause mortality incrementally increased as
follows: STS score 31, STS+BNP 77, STS+BNP+LV-GLS 120,
and STS+BNP+LV-GLS+AVR 140, all P<0.001. Using the
integrated discrimination index, we further demonstrate that
addition of BNP and LV-GLS improved risk stratiﬁcation for
mortality. The results are shown in Figure 1. The ability of
various models to predict mortality incrementally increased as
follows: c-statistic for STS score was 0.60 (0.58–0.64), for
STS score+BNP was 0.67 (0.62–0.70), and STS score+
BNP+LV-GLS was 0.74 (0.68–0.78). The c-statistic for STS
score+BNP+LV-GLS+AVR further increased to 0.79 (0.72–
0.84), all P<0.01.
The proportion of all-cause deaths, separated on the basis
of BNP quartiles was as follows: quartile 1 (14 [11%]), quartile
2 (34 [25%]), quartile 3 (42 [32%]), and quartile 4 (71 [54%]).
Figure 2A illustrates the adjusted survival curves stratiﬁed
according to increasing BNP quartiles (P<0.001). The propor-
tion of deaths, separated on the basis of LV-GLS quartiles was
as follows: quartile 1 (22 [17%]), quartile 2 (33 [25%]), quartile
3 (39 [31%]), and quartile 4 (67 [47%]). Figure 2B illustrates
the adjusted survival curves stratiﬁed according to worsening
LV-GLS quartiles (P<0.001).
Subsequently, in order to understand the interplay
between LV-GLS and BNP, we created 4 subgroups, based
on medians. The proportion of deaths, based on these 4
subgroups, were as follows: (1) LV-GLS≥median (ie, better
value) and BNP <median (21/161 [13%]); (2) LV-GLS ≥median,
BNP≥median (33/102 [32%]); (3) LV-GLS <median, BNP <
median (27/106 [26%]); and (4) LV-GLS <median (ie, worse
value) and BNP ≥median (80/162 [49%]). Figure 3 illustrates
the survival curves according to LV-GLS and BNP medians
(P<0.001).
Table 2. Echocardiographic Characteristics of the Study
Population
Variable Total Population (n=531)
LV ejection fraction (%) 58 (5)
Indexed LVEDD, cm/m2 2.3 (0.4)
Indexed LVESD, cm/m2 1.5 (0.4)
Indexed LA dimension, cm/m2 2.2 (0.5)
Indexed LV mass, g/m2 113 (38)
Diastolic dysfunction
Abnormal relaxation 87%
Pseudonormal 12%
Restrictive filling 1%
LVOT diameter, cm 2.00.2
AV gradient
Peak, mm Hg 74 (30)
Mean, mm Hg 42 (18)
Calculated AV area (continuity equation) 0.77 (0.2)
LV-SVI, mL/m2 39 (10)
LV-SVI <35 mL/m2 202 (38%)
Valvuloarterial impedance, mm HgmLm2 4.72 (1.4)
Aortic regurgitation
None 21%
Mild 54%
Moderate 25%
Mitral regurgitation
None 11%
Mild 71%
Moderate 18%
Tricuspid regurgitation
None 13%
Mild 75%
Moderate 12%
RVSP, mm Hg 37 (13)
LV-GLS (%) 13.9 (3)
LV-GLS quartiles
1st (> 16.3%) 25%
2nd (between (16% to 3% and 14%) 25%
3rd (between 11.6% and 13.9%) 24%
4th (< 11.6%) 26%
All continuous variables reported as mean (SD). AV indicates aortic valve; EDD, end-
diastolic dimension; ESD, end-systolic dimension; LA, left atrium; LV, left ventricle; LV-
GLS, left ventricular global longitudinal strain; LVOT, left ventricular outﬂow tract; LV-SVI,
left ventricular stroke volume index; RVSP, right ventricular systolic pressure.
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The breakdown of deaths, according to symptoms and LV-
GLS/BNP was as follows: asymptomatic and both, LV-GLS
and BNP better than median (5/51 or 10%), asymptomatic
and 1 or both, LV-GLS and BNP worse than median (20/64 or
31%), symptomatic and both, LV-GLS and BNP better than
median (16/110 or 15%) and symptomatic, and 1 or both, LV-
GLS and BNP worse than median (120/306 or 39%). Figure 4
illustrates the survival curves according to symptom status
and whether BNP/LV-GLS were better or worse than median
(P<0.001). Even in asymptomatic patients, the mortality was
signiﬁcantly high in the setting of 1 or both, LV-GLS and BNP
worse than median.
The breakdown of all-cause deaths, according to median
STS score (median 7.3 [3.9–12.9]) and LV-GLS/BNP was as
follows: STS score <median and both, LV-GLS and BNP better
than median (8/79 or 10%), STS score <median and 1 or
both, LV-GLS and BNP worse than median (52/184 or 28%),
STS score ≥median and both, LV-GLS and BNP better than
Table 3. Relevant Characteristics of the Study Population, Separated on Basis of Aortic Valve replacement versus Medical therapy
Variable Medical Therapy (n=126) AVR (n=405) P Value
Age, y 7313 7112 0.05
Male gender 51% 60% 0.04
Angina 26% 38% 0.01
Syncope 7% 6% 0.1
NYHA Class
I 45% 18% <0.001
II 33% 46%
III 15% 29%
IV 2% 7%
Hypertension 78% 79% 0.5
Prior stroke 9% 8% 0.6
Obstructive CAD 47% 63% 0.001
Atrial fibrillation 19% 23% 0.2
Prior OHS 23% 23% 0.5
Society of thoracic surgeons score 11.65 10.96 0.3
b-Blockers 74% 90% <0.001
ACE inhibitors 49% 43% 0.1
Aspirin 72% 95% <0.001
Statins 65% 77% <0.001
GFR, mL/min per 1.73 m2 6935 7430 0.1
Median BNP with IQL, pg/mL 126 (56–264) 171 (81–546) <0.001
LV ejection fraction (%) 575 575 0.6
Indexed LV mass, g/m2 11237 11438 0.1
AV gradient
Peak, mm Hg 5529 8027 <0.001
Mean, mm Hg 3118 4616 <0.001
Calculated AV area (continuity equation) 0.920.2 0.720.2 <0.001
LV-stroke volume index, mL/m2 389 3910 0.4
Valvuloarterial impedance, mm HgmL1m2 4.61.2 4.71.5 0.1
RVSP, mm Hg 3611 3611 0.6
LV-GLS (%) 13.84 13.94 0.9
ACE indicates angiotensin-converting enzyme; AVR, aortic valve replacement; BNP, brain natriuretic peptide; CAD, coronary artery disease; GFR, glomerular ﬁltration rate; IQL, interquartile
range; LV-GLS, left ventricular global longitudinal strain; NYHA, New York Heart Association; OHS, open heart surgery; RVSP, right ventricular systolic pressure.
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median (13/81 or 16%) and STS score ≥median, and 1 or
both, LV-GLS and BNP worse than median (88/187 or 47%).
Figure 5 illustrates the survival curves of patients stratiﬁed
according to STS score and whether BNP/LV-GLS were better
or worse than median (P<0.001). Even in patients with STS
scores lower than median, the mortality was signiﬁcantly high
in the setting of 1 or both, LV-GLS and BNP worse than
median.
Multivariable Cox Proportional Hazard Survival analysis, for
the secondary outcome (cardiac mortality and death due to
unknown causes, excluding noncardiac deaths, n=143)
demonstrated that increasing STS score (hazard ratio 1.05
Figure 1. Reclassiﬁcation of mortality risk in the study sample, based on various models. BNP indicates
brain natriuretic peptide; GLS, global longitudinal strain; IDI, integrated discrimination index; LV-SVI, left
ventricular stroke volume index; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons.
Table 4. Multivariable Cox Proportional Hazard Analysis for All-Cause Mortality in the Study Population
Variable Hazard Ratio P Value
(A) Variables listed below entered in a stepwise fashion*
Age (10-year increase) 1.46 (1.12–1.92) 0.003
NYHA Class 1.27 (1.05–1.54) 0.03
Coronary artery disease 1.72 (1.20–2.46) <0.001
Glomerular filtration rate (for every 10-unit decrease) 1.15 (1.08–1.22) <0.001
BNP (for every 10 pg/mL increase) 1.16 (1.09–1.23) <0.001
Left ventricular global longitudinal strain (for every unit worsening) 1.13 (1.07–1.18) <0.001
Aortic valve surgery (time-dependent covariate analysis) 0.34 (0.23–0.48) <0.001
(B) STS score entered in the model†
Society of Thoracic Surgeons (STS) score 1.05 (1.03–1.07) <0.001
BNP (for every 10 pg/mL increase) 1.14 (1.08–1.22) <0.001
Left ventricular global longitudinal strain (for every unit worsening) 1.09 (1.04–1.15) <0.001
Aortic valve surgery (time-dependent covariate analysis) 0.34 (0.24–0.48) <0.001
*In Part (A), the following variables were considered for analysis: age, sex, symptoms, comorbidities, pacemaker, deﬁbrillator, medications, indexed left ventricular mass and systolic
dimension, left atrial volume index, ejection fraction, diastolic function, stroke volume index, aortic valve area, aortic valve mean gradient, aortic and mitral regurgitation, global longitudinal
strain, brain natriuretic peptide (BNP), aortic valve surgery, and type and time of surgery. NYHA indicates New York Heart Association.
†In Part (B), variables that constitute STS score were not considered for analysis. Other variables are similar to Part (A). Because of collinearity, only stroke volume index (and not
valvuloarterial impedance) was considered for the model. Results are similar if valvuloarterial impedance was considered.
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[1.01–1.09]), every 10 pg/mL increase in BNP (1.08 [1.06–
1.11]), every unit worsening of LV-GLS (hazard ratio 1.12
[1.06–1.18]), and AV surgery (0.36 [0.24–0.52]) were inde-
pendent predictors (v2 for the model 104, P<0001).
Discussion
In our observational study of contemporary patients with
signiﬁcant AS and preserved LVEF, we demonstrate that
Figure 2. Adjusted survival curves demonstrating outcomes based on various quartiles of (A) brain natriuretic peptide (BNP) and (B) left
ventricular global longitudinal strain (LV-GLS).
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increasing BNP levels and worsening LV-GLS were indepen-
dent predictors of mortality, providing additive (rather than
duplicative) prognostic utility. Furthermore, using integrated
discrimination improvement, we demonstrate that addition of
BNP and LV-GLS further improved our ability to reclassify
mortality risk in AS patients. It appears that LV-GLS and BNP
could potentially help us identify patients who could beneﬁt
from earlier AVR. We included patients with patients with AVA
1.0 to 1.3 cm2 because AS is a continuum and we wanted to
evaluate survival of these patients vis-a-vis current therapeu-
tic techniques. Asymptomatic patients had signiﬁcantly worse
survival, in the setting of abnormal LV-GLS and/or BNP. This
impact on survival was also seen in the subgroup with low STS
scores, where patients with LV-GLS and/or BNP worse than
median had signiﬁcantly worse outcomes versus those with
normal LV-GLS and BNP. However, the study is potentially
underpowered to make conclusive assertions about subgroup
analyses; and a larger, prospective study is needed to be
conclusively assertive.
In the current study, when BNP and LV-GLS were
considered for survival analysis, known predictor such as
LV-SVI did not maintain statistical signiﬁcance. This is likely
because sensitive markers such as LV-GLS and BNP
become abnormal earlier in the disease cascade, as
compared to ﬂow-dependent markers such as LV-SVI.
Additionally, there are known inherent technical limitations
in measuring LV-SVI, which takes LVOT area into account.
As previously described, LVOT area can be potentially
inaccurate on 2-dimensional echocardiography when com-
pared to gated computed tomographic techniques.30 This
potentially generates erroneous LV-SVI values, which results
in misclassifying AS patients into different strata with
varying risk proﬁles.
In patients with AS, in order to compensate for increased
wall stress and preserve LVEF, there is progression of LV
hypertrophy. However, LVEF eventually drops and in this
setting, if AVR is not performed, there is a signiﬁcant
reduction in survival. Therefore, objective and sensitive
parameters that identify early LV dysfunction, prior to a drop
in LVEF could potentially have a big impact on appropriate
timing of surgery and in turn, potential survival. BNP is
released in response to increased ventricular wall stress, and
Figure 3. Adjusted survival curves demonstrating outcomes based on 4 subgroups derived based on
brain natriuretic peptide (BNP) and left ventricular global longitudinal strain (LV-GLS) levels better or worse
than median.
DOI: 10.1161/JAHA.115.002561 Journal of the American Heart Association 8
BNP and Strain in Aortic Stenosis Goodman et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
our data are in agreement with previous studies that have
shown that BNP levels correlate with survival.8,10–14 However,
BNP is nonspeciﬁc, with multiple clinical situations resulting in
elevated values. Also, as demonstrated in the current study,
BNP levels appear to be lower in AS patients in particular (and
valvular heart disease in general) than in other etiologies of
heart failure. Hence, different BNP thresholds may be needed
in valvular heart disease to adequately predict outcomes.
Figure 4. Adjusted survival curves demonstrating outcomes of 4 subgroups, based on whether both brain
natriuretic peptide (BNP) and left ventricular global longitudinal strain (LV-GLS) were better than median or
1/both were worse than median and symptoms.
Figure 5. Adjusted survival curves demonstrating outcomes of 4 subgroups, based on whether both brain
natriuretic peptide (BNP) and left ventricular global longitudinal strain (LV-GLS) were better than median or
1/both were worse than median, and STS score better or worse than median.
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A previous report has suggested the use of different
thresholds, based on age and sex.31 A recent report utilized
BNP ratios generated based on these thresholds and demon-
strated incremental prognostic utility of BNP in the setting of
signiﬁcant AS.16 LV-GLS is much more sensitive in detecting
subtle abnormalities in myocardial mechanics and may
indicate pathology before evident on conventional indices of
LV function. Previous studies have indeed demonstrated that
impairment in LV-GLS can occur even in the setting of a
preserved LVEF, due to subendocardial ischemia and ﬁbro-
sis.32,33 Additionally, reduced LV-GLS is associated with
poorer outcomes in patients with signiﬁcant AS,28,34 with
preoperative LV-GLS an independent predictor of postopera-
tive outcomes.11 Using these markers provides synergistic
risk stratiﬁcation in patients with signiﬁcant AS prior to onset
of overt LV systolic dysfunction or symptoms.
Clinical Implications
In patients with signiﬁcant AS and preserved LVEF, a
combination of BNP and LV-GLS provides synergistic risk
stratiﬁcation, independent of symptoms, risk factors, and
echocardiographic variables. Prospective studies are needed
to determine whether onset of changes in these parameters
rather than waiting for symptoms or onset of abnormal LVEF
may be more appropriate to determine valve intervention
timing. Additionally, a risk score, incorporating these markers
alongside other clinical and echocardiographic markers, could
be developed and prospectively validated in asymptomatic
patients with signiﬁcant AS.
Limitations
This was an observational retrospective study conducted at
a large tertiary care center and is likely not free from referral
bias. Not all patients with severe AS seen at our institution
had BNP levels obtained in close proximity to the echocar-
diogram. However, the baseline characteristics of the current
study population were similar to those that did not have BNP
levels measured. During follow-up, only a small proportion of
patients underwent isolated AVR, making this a heteroge-
neous population, where other factors such as coronary
artery disease and aortic disease could have affected
outcomes. However, AS patients tend to be typically older
with many comorbidities, and our study reﬂects the current
state of practice in most valve centers. The biggest utility of
these newer markers would potentially be in asymptomatic
patients with signiﬁcant AS to determine appropriate timing
of surgery, and not in those with symptoms who already
would meet criteria for surgery. However, the study is
potentially underpowered to make conclusive assertions
about this speciﬁc subgroup. We report all-cause mortality
as the primary end point, as opposed to cardiac mortality.
However, on secondary outcomes analysis, where docu-
mented noncardiac deaths were excluded, the basic results
were similar.
Conclusions
In patients with signiﬁcant AS and preserved LVEF, a
combination of BNP and LV-GLS predicts mortality. Assess-
ment of LV-GLS and BNP could have a potential role in
synergistic improvement in risk stratiﬁcation of AS patients
with a preserved LVEF, especially those perceived to be
without symptoms and/or deemed at a low risk.
Future prospective studies are needed to conﬁrm these
observations.
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